Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fentanyl Pectin Nasal Spray for Breakthrough Dyspnea in Cancer
NCT01832402Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2013
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fentanyl (transdermal patch + oral transmucosal lozenge) in Dyspnea, sponsored by University of Texas MD Anderson Cancer Center. Started Jun 2013; status: completed.
02
Drugs
fentanyl (transdermal patch + oral transmucosal lozenge)
03
Conditions
Dyspnea
Beyond the preview
Go deeper on NCT01832402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01832402.